In the United States,<unk>  is indicated for the treatment of adults and children ages one year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of rickets, and for the treatment of people age two and older with tumor-induced osteomalacia (TIO), a rare disease that is characterized by the development of tumors that cause weakened and softened bones. The tumors associated with TIO release a peptide hormone-like substance known as fibroblast growth factor 23 (FGF23) that lowers phosphate levels. In the European Union,<unk>  is indicated for the treatment of X-linked hypophosphataemia with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons. XLH is genetic disorder affecting phosphate metabolism within the body, which results in hypophosphatemia. The disease is characterized by overproduction of the FGF23 hormone in bone cells. The FGF23 hormone is responsible for blocking phosphate re-absorption by the kidney and the suppression of the vitamin D dependent phosphate absorption by the intestine. Due to the excess activity of FGF23, phosphate levels in the blood are abnormally low, which affects the constitution of bone. Thus,<unk>  is designed to bind to the FGF23 receptor and inhibit the excess activity of the FGF23 hormone within the body. While<unk>  is effective for the treatment of X-linked hypophosphatemia, the National Institute for Health and Care Excellence in England and Wales initially raised concerns regarding the incremental cost-effectiveness of the new treatment but the drug is available through a simple discount scheme.
Burosumab
Olaratumab
Alirocumab
Emapalumab
Sarilumab
Evolocumab
Lanadelumab
Dupilumab